OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer

Mar 01, 2021 9:00am EST

OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits

Feb 23, 2021 9:00am EST

OncoSec Appoints Bridget O’Keeffe, Ph.D. as Vice President of Clinical Development

Feb 18, 2021 8:30am EST

OncoSec Strengthens Management Team With Two New Appointments

Feb 02, 2021 9:00am EST

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec’s COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein

Jan 27, 2021 9:00am EST

OncoSec Medical Closes $42.0 Million Public Offering of Common Stock

Jan 25, 2021 4:00pm EST

OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock

Jan 21, 2021 8:30am EST

OncoSec Medical Announces Proposed Public Offering of Common Stock

Jan 20, 2021 4:35pm EST

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

Jan 19, 2021 8:30am EST

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Jan 08, 2021 9:00am EST